A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction
Author(s) -
Ana López,
Suzee E. Lee,
Kevin Wojta,
Eliana Marisa Ramos,
Eric Klein,
Jason Chen,
Adam L. Boxer,
Maria Luisa GornoTempini,
Daniel H. Geschwind,
Lars Schlotawa,
Nikolay V. Ogryzko,
Eileen H. Bigio,
Emily Rogalskı,
Sandra Weıntraub,
Marsel Mesulam,
Angeleen Fleming,
Giovanni Coppola,
Bruce L. Miller,
David C. Rubinsztein
Publication year - 2017
Publication title -
brain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.142
H-Index - 336
eISSN - 1460-2156
pISSN - 0006-8950
DOI - 10.1093/brain/awx005
Subject(s) - frontotemporal dementia , progressive supranuclear palsy , neurodegeneration , autophagy , frontotemporal lobar degeneration , tau protein , tauopathy , zebrafish , dementia , disease , medicine , alzheimer's disease , neuroscience , biology , genetics , gene , apoptosis
Mutations in the gene encoding tau (MAPT) cause frontotemporal dementia spectrum disorders. A rare tau variant p.A152T was reported as a risk factor for frontotemporal dementia spectrum and Alzheimer's disease in an initial case-control study. Such findings need replication in an independent cohort. We analysed an independent multinational cohort comprising 3100 patients with neurodegenerative disease and 4351 healthy control subjects and found p.A152T associated with significantly higher risk for clinically defined frontotemporal dementia and progressive supranuclear palsy syndrome. To assess the functional and biochemical consequences of this variant, we generated transgenic zebrafish models expressing wild-type or A152T-tau, where A152T caused neurodegeneration and proteasome compromise. Impaired proteasome activity may also enhance accumulation of other proteins associated with this variant. We increased A152T clearance kinetics by both pharmacological and genetic upregulation of autophagy and ameliorated the disease pathology observed in A152T-tau fish. Thus, autophagy-upregulating therapies may be a strategy for the treatment for tauopathies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom